U.S. Markets closed
  • S&P Futures

    3,693.75
    -15.25 (-0.41%)
     
  • Dow Futures

    29,559.00
    -110.00 (-0.37%)
     
  • Nasdaq Futures

    11,332.25
    -44.50 (-0.39%)
     
  • Russell 2000 Futures

    1,678.40
    -7.70 (-0.46%)
     
  • Crude Oil

    79.17
    +0.43 (+0.55%)
     
  • Gold

    1,648.30
    -7.30 (-0.44%)
     
  • Silver

    18.73
    -0.18 (-0.98%)
     
  • EUR/USD

    0.9703
    -0.0135 (-1.3681%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0815
    -0.0439 (-3.9032%)
     
  • USD/JPY

    143.3140
    +0.9790 (+0.6878%)
     
  • BTC-USD

    18,789.13
    -116.51 (-0.62%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.27 (-0.58%)
     

Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference

·1 min read
Surface Oncology, Inc.
Surface Oncology, Inc.

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at https://investors.surfaceoncology.com/. In addition, a replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com